A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy

OBJECTIVE: Currently, the only approved standard Duchenne muscular dystrophy (DMD) treatment in Japan is oral steroids, which have various disadvantages. Previous work has suggested that hematopoietic‐type prostaglandin D synthase (HPGDS), involved in production of the inflammatory mediator prostagl...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, Eri, Komaki, Hirofumi, Shimizu‐Motohashi, Yuko, Ishiyama, Akihiko, Sasaki, Masayuki, Takeda, Shin'ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243382/
https://www.ncbi.nlm.nih.gov/pubmed/30480028
http://dx.doi.org/10.1002/acn3.651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243382/
https://www.ncbi.nlm.nih.gov/pubmed/30480028
http://dx.doi.org/10.1002/acn3.651

Ejemplares similares